Mahnum Shahzad, Huseyin Naci, Anita Katharina Wagner
Abstract
This exploratory study assesses estimated Medicare spending on 10 cancer drug indications that lacked overall survival benefit after receiving US Food and Drug Administration accelerated approval.
OpenAlex reports 26 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This exploratory study assesses estimated Medicare spending on 10 cancer drug indications that lacked overall survival benefit after receiving US Food and Drug Administration accelerated approval.
Key concepts: Medicine, Food and drug administration, Drug, Cancer drugs, Drug approval, Drug administration, Intensive care medicine, Cancer